RemeGen Co. Ltd. Class H (REGMF) Stock Price & Analysis
REGMF Stock Chart & Stats
- Day’s Range
- $8.18 - $8.43
- 52-Week Range
- $7.47 - $13.31
- Previous Close
- $8.12
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $6.60B
- Enterprise Value
- $37.50B
- Total Cash (Recent Filing)
- $5.51B
- Total Debt (Recent Filing)
- $292.23M
- Price to Earnings (P/E)
- 7.9
- Beta
- 2.95
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.13
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Profitability Inflection
The sharp TTM revenue increase and exceptionally high profitability demonstrate substantial current commercial traction for the company’s therapies. If these results persist, stronger earnings can support reinvestment in clinical development, commercialization, and the broader proprietary product pipeline over coming quarters.
Strong Cash Conversion
Operating and free cash flow closely tracking net income indicates that reported TTM earnings are converting into liquidity rather than remaining primarily accounting gains. This improves the company’s ability to fund operations and development internally, reducing dependence on external capital.
Much Lower Financial Leverage
The substantially lower debt-to-equity ratio gives RemeGen greater financial flexibility and reduces the burden of debt service compared with prior years. A stronger capital structure can help the company sustain research, commercialization, and other investment while absorbing operating volatility.
Bears Say
Earnings Durability Remains Uncertain
The abrupt shift from losses and cash burn to exceptionally high profitability makes the current earnings base difficult to underwrite as a stable trend. Results may remain lumpy if they depend on product mix, milestones, or other factors that do not repeat consistently.
Historically Inconsistent Cash Generation
Although current cash generation is strong, the prior record shows that RemeGen has not yet demonstrated consistent cash production through a full operating cycle. Repeated historical outflows indicate that future funding needs could rise again if profitability or product economics weaken.
Free Cash Flow Growth Is Negative
Negative TTM free cash flow growth tempers the significance of the current cash-flow level and suggests that liquidity generation is not accelerating. Without renewed growth, the company may have less internally generated capacity to expand commercialization or advance its development programs.
RemeGen Co. Ltd. Class H News
REGMF FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
What is RemeGen Co. Ltd. Class H’s market cap?
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
Is RemeGen Co. Ltd. Class H overvalued?
Does RemeGen Co. Ltd. Class H pay dividends?
What is RemeGen Co. Ltd. Class H’s EPS estimate?
How many shares outstanding does RemeGen Co. Ltd. Class H have?
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
RemeGen Co. Ltd. Class H Stock Smart Score
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jian Min Fang
- Employees
- 3,048
- Website
- www.remegen.com
- Address
- 58 Middle Beijing Road, Yantai, SD, 264000, CN
RemeGen Co. Ltd. Class H (REGMF) Earnings & Revenues
REGMF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 12 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 3 | 0 | 9 |










